Novo-Nordisk A/S (NVO) Stock Price

NVOStock

$38.83−28.02%52W

Market Cap$171.36B

P/E11.40x

PEG Ratio4.29

Div yield1.00%

Beta1.96

NVO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-4.44%

Price vs S&P 500 (4W)1.17%

PEG Ratio4.29

VGM Score58.95

P/E Ratio (Annual)11.40x

Indicated Dividend Yield (Annual)1.00%

P/CF (Annual)9.81x

Book Value / Share (Quarterly)$7.52

P/TBV (Annual)17.22x

Indicated Dividend (Annual)$1.76

Revenue Growth (3Y)20.43%

Cash Flow / Share (Quarterly)$1.66

Payout Ratio (TTM)54.86%

Price vs S&P 500 (YTD)-32.11%

Gross Margin (TTM)80.65%

Net Profit Margin (TTM)35.35%

EPS (TTM)$3.94

10-Day Avg Trading Volume4.94M

EPS Excl Extra (TTM)$3.94

Revenue Growth (5Y)19.48%

EPS (Annual)$3.46

Dividend / Share (Annual)$1.75

ROI (Annual)31.52%

Gross Margin (Annual)80.98%

Net Profit Margin (5Y Avg)33.85%

Cash / Share (Quarterly)$1.53

P/E Basic Excl Extra (TTM)10.03x

Revenue Growth QoQ (YoY)2.12%

EPS Growth (5Y)20.66%

P/E Normalized (Annual)11.40x

ROA (Last FY)18.87%

Revenue Growth TTM (YoY)5.61%

EBITD / Share (TTM)$5.73

ROE (5Y Avg)67.14%

Operating Margin (TTM)43.13%

Cash Flow / Share (Annual)$0.98

P/B Ratio5.28x

P/B Ratio (Quarterly)4.82x

Net Income / Employee (Annual)$223,978

EV / Revenue (TTM)3.84x

Net Interest Coverage (TTM)149.07x

ROA (TTM)21.08%

EPS Growth QoQ (YoY)-20.61%

EV / EBITDA (TTM)7.46x

EPS Incl Extra (Annual)$3.46

Current Ratio (Annual)0.80x

Quick Ratio (Quarterly)0.66x

3-Month Avg Trading Volume4.63M

52-Week Price Return-28.02%

EV / Free Cash Flow (Annual)43.58x

P/E Incl Extra (TTM)10.03x

Revenue / Employee (TTM)$720,325

Tangible BV / Share (Quarterly)$4.05

P/S Ratio (Annual)3.78x

Asset Turnover (Annual)0.57x

52-Week High$61.67

Operating Margin (5Y Avg)42.72%

EPS Excl Extra (Annual)$3.46

CapEx CAGR (5Y)32.48%

Tangible BV CAGR (5Y)14.46%

26-Week Price Return5.46%

Quick Ratio (Annual)0.57x

13-Week Price Return-20.85%

Total Debt / Equity (Annual)0.67x

Current Ratio (Quarterly)0.87x

Enterprise Value$190.05B

Revenue / Share Growth (5Y)20.70%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)23.06%

Revenue / Employee (Annual)$675,785

Inventory Turnover (Annual)1.30x

Pretax Margin (Annual)42.24%

Cash / Share (Annual)$0.91

3-Month Return Std Dev33.17%

Gross Margin (5Y Avg)83.54%

Net Income / Employee (TTM)$254,604

EBITDA CAGR (5Y)21.59%

EBITDA Interim CAGR (5Y)18.49%

ROE (Last FY)52.79%

Net Interest Coverage (Annual)145.49x

EPS Basic Excl Extra (Annual)$3.46

P/FCF (TTM)13.72x

Receivables Turnover (TTM)4.16x

EV / Free Cash Flow (TTM)25.83x

Total Debt / Equity (Quarterly)0.63x

EPS Incl Extra (TTM)$3.94

Receivables Turnover (Annual)4.33x

ROI (TTM)35.64%

Dividend Growth Rate (5Y)19.05%

P/S Ratio (TTM)3.54x

Pretax Margin (5Y Avg)42.42%

Revenue / Share (Annual)$10.45

Tangible BV / Share (Annual)$2.84

Forward P/E11.50x

Free OCF CAGR (5Y)-0.60%

Price vs S&P 500 (52W)-43.55%

P/E Ratio (TTM)10.03x

EPS Growth TTM (YoY)4.93%

Year-to-Date Return-20.18%

5-Day Price Return1.25%

EPS Normalized (Annual)$3.46

ROA (5Y Avg)22.94%

Net Profit Margin (Annual)33.14%

Month-to-Date Return2.53%

Cash Flow / Share (TTM)$2.76

EBITD / Share (Annual)$5.06

EPS Growth (3Y)23.53%

Operating Margin (Annual)41.30%

LT Debt / Equity (Annual)0.61x

P/CF (TTM)8.78x

ROI (5Y Avg)47.01%

P/E Excl Extra (TTM)10.03x

LT Debt / Equity (Quarterly)0.55x

EPS Basic Excl Extra (TTM)$3.94

P/TBV (Quarterly)8.95x

Payout Ratio (Annual)50.53%

P/B Ratio (Annual)7.44x

Dividend / Share (TTM)$1.76

Inventory Turnover (TTM)1.31x

Pretax Margin (TTM)45.15%

Book Value / Share (Annual)$6.58

Price vs S&P 500 (13W)-23.54%

Net Margin Growth (5Y)-0.03%

Dividend Yield (TTM)4.45%

Beta1.96x

P/FCF (Annual)40.29x

Revenue / Share (TTM)$11.17

ROE (TTM)59.09%

52-Week Low$33.73

vGradeB

gGradeC

mGradeC

vgmGradeC

NVO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$0.75	$0.93	+24.01%(+$0.18)
Q1 2026	May 6, 2026	$1.05	$1.00	-4.75%(-$0.05)
Q4 2025	Feb 3, 2026	$0.89	$0.91	+2.34%(+$0.02)
Q3 2025	Nov 5, 2025	$0.64	$0.68	+6.05%(+$0.04)
Q2 2025	Aug 6, 2025	$0.90	$0.90	-0.74%(-$0.01)

NVO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.38

3.41

3.33

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Novo-Nordisk A/S

Novo Nordisk is the global leader in diabetes care, commanding approximately one-third of the branded diabetes treatment market. The Danish company manufactures insulins, GLP-1 therapies, oral antidiabetics, and obesity treatments. Its smaller biopharmaceutical segment, representing less than 10% of revenue, develops protein therapies for hemophilia and related disorders.